A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)

This is an phase II study to prelininarily evaluate the efficacy and safety of JS212 mono therapy or combination therapy in patients with recurrent or metastatic TNBC.

Trial Details

NCT ID
NCT07876557
Phase
PHASE2
Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • JS212 in combination with JS207
  • JS212 monotherapy
  • JS212 in combination with JS001
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Lanzhou, Gansu, China|36.05701,103.83987
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Male or female age 18-70 years old;
  • Voluntary participation in clinical study;
  • Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression);
  • No prior systemic antitumor therapy for locally advanced or Metastatic TNBC(cohort expansion period); only one line of prior systemetic treatment f…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →